Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
| Brand name | ADBRY |
| Generic name | TRALOKINUMAB-LDRM |
| Active ingredient(s) | TRALOKINUMAB |
| Distributed by / for | LEO Pharma Inc., Madison, NJ 07940, USA |
| NDC | 50222-350-91 |
| Full product label | Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO Pharma Inc., Madison, NJ 07940, USA, |
| Recalling firm | LEO PHARMA INC |
| Distribution | Nationwide in the USA |
| Quantity | 11,407 units |
| Recall initiated | 2026-02-10 |
| Report date | 2026-03-04 |
| Recall completed | — |
| Recall number | D-0339-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Madison NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗